ErbB Activation via a Metalloprotease by Angiotensin II
血管紧张素 II 通过金属蛋白酶激活 ErbB
基本信息
- 批准号:7188543
- 负责人:
- 金额:$ 32.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-03-01 至 2009-07-14
- 项目状态:已结题
- 来源:
- 关键词:Angiotensin IIAtherosclerosisBlood VesselsCardiovascular DiseasesCytoplasmic TailDevelopmentDiseaseEpidermal Growth Factor ReceptorFamilyGTP-Binding ProteinsHyperplasiaHypertensionHypertrophyInjuryLigandsMediatingMetalloproteasesMolecularPlayProductionProtein Tyrosine KinaseRoleSecond Messenger SystemsSignal TransductionSmooth Muscle MyocytesTestingTransactivationVascular remodelingdesignmigrationnovelreceptorrestenosissecond messengervascular smooth muscle cell migration
项目摘要
DESCRIPTION (provided by applicant): Angiotensin II (Angll) and its G protein-coupled AT1 receptor play critical roles in mediating cardiovascular diseases such as hypertension, atherosclerosis, and restenosis after vascular injury. It is widely believed that Angll promotes these diseases by inducing vascular remodeling that involves hypertrophy, hyperplasia, and migration of vascular smooth muscle cells (VSMCs). It has been shown that transactivation of an ErbB family receptor, EGF receptor (ErbB1/EGFR), is essential for VSMC hypertrophy and migration by Angll. However, the precise signal transduction mechanism by which Angll transactivates EGFR/ErbB1 and whether other ErbBs are also required for Angll function remains unclear. Recent studies suggest an involvement of a metalloprotease-dependent ErbB family ligand production in the transactivation. Thus, our central hypothesis is that an AT1-derived second messenger promotes activation of ADAM metalloprotease leading to ErbB receptors transactivation and subsequent remodeling in VSMCs. Our past and current preliminary studies strongly support our central hypothesis. Therefore, the specific aims of this application are designed to identify the signaling mechanism(s) and functional significance of the metalloprotease/ErbB activation by Angll in VSMCs. The specific aims of the study are: Aim 1. To test the hypothesis that G protein and second messengers are involved in metalloprotease activation through the AT1 receptor. Aim 2. To test the hypothesis that ADAM metalloprotease is activated by a mechanism involving ADAM cytoplasmic tail and a cytosolic tyrosine kinase. Aim 3. To test the hypothesis that several ErbB ligands are produced by Angll and mediate Angll-induced transactivation of ErbB receptors. Aim 4. To test the hypothesis that the transactivation of ErbB receptors is required for hypertrophy and migration of VSMCs induced by Angll. Accomplishment of these specific aims will not only give us a better understanding of the critical molecular mechanism underlying vascular remodeling stimulated by Angll but will also contribute to development of novel treatment strategies toward cardiovascular diseases.
描述(由申请人提供):血管紧张素II(AngII)及其G蛋白偶联的AT 1受体在介导心血管疾病如高血压、动脉粥样硬化和血管损伤后再狭窄中起关键作用。普遍认为AngII通过诱导涉及血管平滑肌细胞(VSMC)的肥大、增生和迁移的血管重塑来促进这些疾病。已经显示ErbB家族受体EGF受体(ErbB 1/EGFR)的反式激活对于血管平滑肌细胞肥大和AngII的迁移是必需的。然而,AngII反式激活EGFR/ErbB 1的精确信号转导机制以及AngII功能是否也需要其他ErbB仍不清楚。最近的研究表明,金属蛋白酶依赖的ErbB家族配体的生产参与反式激活。因此,我们的中心假设是AT 1衍生的第二信使促进ADAM金属蛋白酶的激活,导致ErbB受体的反式激活和随后的重塑VSMC。我们过去和现在的初步研究强烈支持我们的中心假设。因此,本申请的具体目的被设计为鉴定VSMC中AngII激活金属蛋白酶/ErbB的信号传导机制和功能意义。研究的具体目标是:目标1。验证G蛋白和第二信使通过AT 1受体参与金属蛋白酶激活的假设。目标2.验证ADAM金属蛋白酶通过涉及ADAM胞质尾区和胞质酪氨酸激酶的机制激活的假设。目标3。为了检验几种ErbB配体由AngII产生并介导AngII诱导的ErbB受体反式激活的假设。目标4。为了验证ErbB受体的反式激活是AngII诱导的VSMCs肥大和迁移所必需的假设。这些特定目标的实现不仅使我们更好地理解AngII刺激血管重塑的关键分子机制,而且还将有助于开发针对心血管疾病的新治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SATORU EGUCHI其他文献
SATORU EGUCHI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SATORU EGUCHI', 18)}}的其他基金
Roles of aging and cellular senescence in the development of intracranial aneurysm rupture
衰老和细胞衰老在颅内动脉瘤破裂发展中的作用
- 批准号:
10680060 - 财政年份:2023
- 资助金额:
$ 32.11万 - 项目类别:
EGF-ADAM17 axis in the pathophysiology of intracranial aneurysm
EGF-ADAM17轴在颅内动脉瘤病理生理学中的作用
- 批准号:
10477257 - 财政年份:2019
- 资助金额:
$ 32.11万 - 项目类别:
EGF-ADAM17 axis in the pathophysiology of intracranial aneurysm
EGF-ADAM17轴在颅内动脉瘤病理生理学中的作用
- 批准号:
10024093 - 财政年份:2019
- 资助金额:
$ 32.11万 - 项目类别:
EGF-ADAM17 axis in the pathophysiology of intracranial aneurysm
EGF-ADAM17轴在颅内动脉瘤病理生理学中的作用
- 批准号:
10242175 - 财政年份:2019
- 资助金额:
$ 32.11万 - 项目类别:
EGF-ADAM17 axis in the pathophysiology of intracranial aneurysm
EGF-ADAM17轴在颅内动脉瘤病理生理学中的作用
- 批准号:
10686891 - 财政年份:2019
- 资助金额:
$ 32.11万 - 项目类别:
Inflammatory Responses of The Visceral Adipose Tissue Microcirculation
内脏脂肪组织微循环的炎症反应
- 批准号:
9906206 - 财政年份:2017
- 资助金额:
$ 32.11万 - 项目类别:
Inflammatory Responses of The Visceral Adipose Tissue Microcirculation
内脏脂肪组织微循环的炎症反应
- 批准号:
9318746 - 财政年份:2017
- 资助金额:
$ 32.11万 - 项目类别:
Vascular signal as a therapeutic target for abdominal aortic aneurysm
血管信号作为腹主动脉瘤的治疗靶点
- 批准号:
9310410 - 财政年份:2015
- 资助金额:
$ 32.11万 - 项目类别:
Vascular signal as a therapeutic target for abdominal aortic aneurysm
血管信号作为腹主动脉瘤的治疗靶点
- 批准号:
8940888 - 财政年份:2015
- 资助金额:
$ 32.11万 - 项目类别:
Vascular signal as a therapeutic target for abdominal aortic aneurysm
血管信号作为腹主动脉瘤的治疗靶点
- 批准号:
9100916 - 财政年份:2015
- 资助金额:
$ 32.11万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 32.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Body composition and atherosclerosis-related biomarkers in women with endometriosis
子宫内膜异位症女性的身体成分和动脉粥样硬化相关生物标志物
- 批准号:
23K15842 - 财政年份:2023
- 资助金额:
$ 32.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Targeted multimodal stimuli-responsive nanogels for atherosclerosis imaging and therapy
用于动脉粥样硬化成像和治疗的靶向多模式刺激响应纳米凝胶
- 批准号:
2880683 - 财政年份:2023
- 资助金额:
$ 32.11万 - 项目类别:
Studentship
The Epigenetic Regulator Prdm16 Controls Smooth Muscle Phenotypic Modulation and Atherosclerosis Risk
表观遗传调节因子 Prdm16 控制平滑肌表型调节和动脉粥样硬化风险
- 批准号:
10537602 - 财政年份:2023
- 资助金额:
$ 32.11万 - 项目类别:
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
- 批准号:
10652788 - 财政年份:2023
- 资助金额:
$ 32.11万 - 项目类别:
Novel Mechanisms Underlying the Development of Atherosclerosis
动脉粥样硬化发展的新机制
- 批准号:
10589484 - 财政年份:2023
- 资助金额:
$ 32.11万 - 项目类别:
Alcohol Regulation of Endothelial Plasticity in Atherosclerosis
酒精对动脉粥样硬化内皮可塑性的调节
- 批准号:
10585070 - 财政年份:2023
- 资助金额:
$ 32.11万 - 项目类别:
From genotype to phenotype in a GWAS locus: the role of REST in atherosclerosis
GWAS 位点从基因型到表型:REST 在动脉粥样硬化中的作用
- 批准号:
10570469 - 财政年份:2023
- 资助金额:
$ 32.11万 - 项目类别:
The role of extracellular vesicle-associated MicroRNAs in HIV-associated atherosclerosis
细胞外囊泡相关 MicroRNA 在 HIV 相关动脉粥样硬化中的作用
- 批准号:
10619831 - 财政年份:2023
- 资助金额:
$ 32.11万 - 项目类别: